- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03233997
CSD170302: Study to Assess Nicotine Uptake in Smokers From Electronic Cigarettes
CSD170302: An Unblinded, Parallel, Randomized Study to Assess Nicotine Uptake in Smokers From Electronic Cigarettes
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Colorado
-
Lakewood, Colorado, Verenigde Staten, 80228
- Davita Clinical Research
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Able to read, understand, and willing to sign an ICF and complete questionnaires written in English.
- Generally healthy males and females, 21 to 60 years of age, inclusive, at Screening Visit.
Subjects must meet one (a or b) of the following tobacco use conditions:
- Exclusive cigarette smoker who self-reports smoking at least (≥) 10 cigarettes per day for at least 6 months prior to Screening Visit. Brief periods of abstinence more than 30 days prior to screening due to illness, quit attempt or clinical study participation will be allowed at the discretion of the Investigator.
- Dual user of combustible cigarettes and electronic cigarettes (EC) who self-reports:
i. Smoking at least (≥) 10 cigarettes per day for at least 6 months prior to Screening Visit. Brief periods of abstinence more than 30 days prior to screening due to illness, quit attempt or clinical study participation will be allowed at the discretion of the Investigator and ii. Using a nicotine-containing cig-a-like EC or a tank system EC either daily or at least weekly for at least 3 months prior to Screening Visit.
- Willing to be confined overnight and abstain from tobacco- and nicotine- containing product use for 12 hours prior to IP use through Study Discharge.
- Willing to use assigned IP during the study according to protocol.
- Expired breath carbon monoxide (ECO) level is ≥10 parts per million (ppm) at the Screening Visit and Study Day 1.
- Positive urine cotinine test at the Screening Visit and Study Day 1.
- No intent to quit smoking or vaping from the Screening Visit to Study Day 2.
- Females must be willing to use a form of contraception acceptable to the Investigator from the time of signing informed consent until Study Discharge, or be surgically sterile for at least 90 days prior to the Screening Visit.
Exclusion Criteria:
- Presence of clinically significant or unstable/uncontrolled acute or chronic medical conditions at the Screening Visit, as determined by the Investigator, that would preclude a subject from participating safely in the study (e.g., uncontrolled hypertension, diabetes, asthma or other lung disease, cardiac disease, neurological disease or psychiatric disorders) based on safety assessments such as clinical laboratory tests, pregnancy tests, medical history, and physical/oral examinations.
- At risk for heart disease, as determined by the Investigator.
- Systolic blood pressure of > 160 mmHg or a diastolic blood pressure of > 95 mmHg, measured after being seated for 5 minutes.
- Weight of ≤ 110 pounds.
- Poor peripheral venous access.
- Use of medicine for treatment of depression, unless on a stable dose for the past 6 months prior to screening and deemed clinically stable by the PI.
- Current scheduled treatment for asthma within the past consecutive 12 months prior to screening. As needed treatment, such as inhalers, may be included at the PIs discretion pending approval from the medical monitor.
- Any history of cancer, except for primary cancers of skin such as localized basal cell/squamous cell carcinoma that has been surgically and / or cryogenically removed.
- Use of any medication or substance that aids in smoking cessation, including but not limited to any nicotine replacement therapy (NRT) (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), or lobelia extract within 30 days prior to the Screening Visit.
- History or presence of hemophilia or other bleeding disorders.
- History or presence of clotting disorders with concomitant use of anticoagulants (e.g., clopidogrel [Plavix®], warfarin [Coumadin®, Jantoven®] or aspirin [> 325 mg/day]).
- Participation in another clinical trial within (≤) 30 days prior to the time of consent. The 30-day window for each subject will be derived from the date of the last study event in the previous study to the time of consent of the current study.
- Positive test for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), or Hepatitis C virus antibody (anti-HCV).
- Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.
- Females ≥ 35 years of age currently using systemic, estrogen-containing contraception or hormone replacement therapy.
- A positive urine drug screen without disclosure of prescribed corresponding concomitant medication(s) at the Screening Visit or on Study Day 1.
- A positive alcohol breathalyzer result at the Screening Visit or on Study Day 1.
- Employed by a tobacco or nicotine company, the study site, or handles tobacco or nicotine-containing products as part of their job.
- Determined by the Investigator to be inappropriate for the study, including a subject who is unable to communicate or unwilling to cooperate with the clinical staff.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: FT21018 Group
7 day at-home use of electronic cigarette FT21018 followed by a 2 day in-clinic period.
|
An electronic cigarette
|
Experimenteel: FT21033 Group
7 day at-home use of electronic cigarette FT21033 followed by a 2 day in-clinic period.
|
An electronic cigarette
|
Experimenteel: FT21034 Group
7 day at-home use of electronic cigarette FT21034 followed by a 2 day in-clinic period.
|
An electronic cigarette
|
Experimenteel: FT21035 Group
7 day at-home use of electronic cigarette FT21035 followed by a 2 day in-clinic period.
|
An electronic cigarette
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Cmax (maximale baseline-aangepaste nicotineplasmaconcentratie)
Tijdsspanne: -5, -0,5, 3, 5, 8, 10, 11, 12, 15, 20, 30, 60 minuten
|
Om de opname van nicotine te beoordelen aan het begin van een gebruiksperiode van 10 minuten ad libitum Investigational Product (IP).
|
-5, -0,5, 3, 5, 8, 10, 11, 12, 15, 20, 30, 60 minuten
|
AUCnic0-60
Tijdsspanne: -5, -0,5, 3, 5, 8, 10, 11, 12, 15, 20, 30, 60 minuten
|
Gebied onder de voor de basislijn aangepaste nicotineconcentratie-versus-tijd-curve van tijd nul tot 60 minuten na het begin van een ad libitum IP-gebruiksperiode van 10 minuten.
|
-5, -0,5, 3, 5, 8, 10, 11, 12, 15, 20, 30, 60 minuten
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
PLover het algemeen
Tijdsspanne: 13 minuten
|
Algehele productaanbeveling (PL) is een aanvullende maatstaf voor hoeveel het onderwerp van het product houdt, en is een indicatie van hun potentiële bereidheid om het product op een later tijdstip opnieuw te gebruiken; gemeten 13 minuten na het begin van IP-gebruik.
|
13 minuten
|
Tmax
Tijdsspanne: -5, -0.5, 3, 5, 8, 10, 12, 15 Minutes
|
Maximum baseline-adjusted plasma nicotine concentration from time zero to 15 minutes after the start of IP use.
|
-5, -0.5, 3, 5, 8, 10, 12, 15 Minutes
|
AUCnic0-15
Tijdsspanne: -5, -0.5, 3, 5, 8, 10, 12, 15 Minutes
|
Area under the baseline-adjusted nicotine concentration-versus-time curve from time zero to 15 minutes after the start of IP use.
|
-5, -0.5, 3, 5, 8, 10, 12, 15 Minutes
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Elizabeth Yoon, MSN, FNP-C, Davita Clinical Research
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- CSD170302
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Roken
-
Boston UniversityFlight Attendant Medical Research InstituteVoltooid
-
Cedars-Sinai Medical CenterUniversity of California, San FranciscoVoltooidTweedehands smoking | Vasculaire verouderingVerenigde Staten
-
Peking Union Medical College HospitalRun Shaw Hospital, Zhejiang University School of Medicine; Hangzhou Medisol Technology...Nog niet aan het wervenTweedehands smoking | Passief roken | Verontreiniging door tabaksrookChina
-
Mustafa Kemal UniversityOnbekendTweedehands smokingKalkoen
Klinische onderzoeken op FT21018
-
RAI Services CompanyVince & Associates Clinical Research, Inc.Voltooid